Literature DB >> 16413228

Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

Cassia N Cearley1, John H Wolfe.   

Abstract

Recombinant adeno-associated viral (AAV) vectors can transduce cells of the CNS, resulting in long-term expression. AAV vector transduction varies depending on the serotype used and the region of the brain injected. AAV serotypes 7, 8, 9, and Rh10 have recently become available, but the transduction capabilities of these serotypes within the CNS have not been determined. We show that AAV 7, 8, 9, and Rh10 vectors expressing cDNA for a lysosomal enzyme transduce neurons, but not astrocytes or oligodendrocytes, in the cortex, striatum, hippocampus, and thalamus. Although all of the vectors contained the same genome, there were markedly different transduction patterns that could be due only to the differences in capsid proteins. The AAV 9 vector was found to undergo vector genome transport to distal neuronal cell bodies via known axonal pathways. This facilitated the distribution of enzyme, resulting in correction of lysosomal storage lesions in regions of a diseased brain that would not be corrected if the genome were not transported.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413228     DOI: 10.1016/j.ymthe.2005.11.015

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  176 in total

1.  Specific disruption of astrocytic Ca2+ signaling pathway in vivo by adeno-associated viral transduction.

Authors:  Y Xie; T Wang; G Y Sun; S Ding
Journal:  Neuroscience       Date:  2010-08-22       Impact factor: 3.590

2.  Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection.

Authors:  Thomas J Giove; Miguel Sena-Esteves; William D Eldred
Journal:  Exp Eye Res       Date:  2010-08-17       Impact factor: 3.467

3.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

4.  Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice.

Authors:  Rachel D Penrod; Audrey M Wells; William A Carlezon; Christopher W Cowan
Journal:  Curr Protoc Neurosci       Date:  2015-10-01

Review 5.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

Review 6.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

7.  Disrupting function of FK506-binding protein 1b/12.6 induces the Ca²+-dysregulation aging phenotype in hippocampal neurons.

Authors:  John C Gant; Kuey-Chu Chen; Christopher M Norris; Inga Kadish; Olivier Thibault; Eric M Blalock; Nada M Porter; Philip W Landfield
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

Review 8.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

9.  Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states.

Authors:  Ronald L Klein; Robert D Dayton; Jason B Tatom; Cynthia G Diaczynsky; Michael F Salvatore
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

10.  Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.

Authors:  S K Powell; N Khan; C L Parker; R J Samulski; G Matsushima; S J Gray; T J McCown
Journal:  Gene Ther       Date:  2016-09-15       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.